scholarly journals Applying New Research Criteria for Diagnosis of Early Alzheimer's Disease: Sex and Intelligence Matter

2009 ◽  
Vol 2009 ◽  
pp. 1-6 ◽  
Author(s):  
U. Beinhoff ◽  
H. Tumani ◽  
M. W. Riepe
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Episodic Memory ◽  
Memory Function ◽  
Memory Deficits ◽  
Intellectual Ability ◽  
Neurodegenerative Process ◽  
Using Data ◽  
New Research ◽  
Research Criteria

Alzheimer's disease (AD) can be diagnosed according to new research criteria proposed recently (Dubois et al., 2007). Diagnosis is made on grounds of episodic memory deficits and one pathological biomarker: cerebrospinal fluid (CSF) or structural/functional imaging. Goal was to investigate the dependence of episodic memory function on material (verbal, visuospatial), gender and premorbid intellectual ability (IQ). The new research criteria of AD were applied retrospectively using data of 68 patients (Mini-Mental-Status Examination, MMSE 22) from a university memory clinic. Women with lower IQ performed worse on visuospatial episodic memory than women with higher IQ and men with the same IQ. Thus, women with lower IQ appear to be particularly vulnerable tovisuospatialepisodic memory deficits despite similar CSF tau values indicating a similar activity of the neurodegenerative process. Gender, premorbid IQ, and visuospatial material need to be considered in the assessment of episodic memory breakdown applying the newly proposed research criteria for the diagnosis of AD.

Impact of Comorbid Depression on Serial Position Effects in Alzheimer’s Disease

GeroPsych ◽  
2014 ◽  
Vol 27 (4) ◽  
pp. 161-169 ◽  
Author(s):  
Nienke A. Hofrichter ◽  
Sandra Dick ◽  
Thomas G. Riemer ◽  
Carsten Schleussner ◽  
Monique Goerke ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Serial Position ◽  
Episodic Memory ◽  
Memory Performance ◽  
Memory Function ◽  
Word List ◽  
Position Effects ◽  
Serial Position Effects ◽  
List Memory

Hippocampal dysfunction and deficits in episodic memory have been reported for both Alzheimer’s disease (AD) and major depressive disorder (MDD). Primacy performance has been associated with hippocampus-dependent episodic memory, while recency may reflect working memory performance. In this study, serial position profiles were examined in a total of 73 patients with MDD, AD, both AD and MDD, and healthy controls (HC) by means of CERAD-NP word list memory. Primacy performance was most impaired in AD with comorbid MDD, followed by AD, MDD, and HC. Recency performance, on the other hand, was comparable across groups. These findings indicate that primacy in AD is impaired in the presence of comorbid MDD, suggesting additive performance decrements in this specific episodic memory function.

P1-371: New research criteria for the diagnosis of Alzheimer's disease applied in a memory clinic population

2008 ◽  
Vol 4 ◽  
pp. T327-T328 ◽  
Author(s):  
Femke H. Bouwman ◽  
Nicolaas A. Verwey ◽  
Martin Klein ◽  
Yolande A.L. Pijnenburg ◽  
Astrid Kok ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Memory Clinic ◽  
New Research ◽  
Research Criteria ◽  
Clinic Population

Depression does not aggravate the episodic memory deficits associated with Alzheimer's disease.

1999 ◽  
Vol 13 (4) ◽  
pp. 532-538 ◽  
Author(s):  
Kjell Fahlander ◽  
Anna-Karin Berger ◽  
Åke Wahlin ◽  
Lars Bäckman
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Episodic Memory ◽  
Memory Deficits

scholarly journals Ameliorative Properties of Boronic Compounds in In Vitro and In Vivo Models of Alzheimer’s Disease

2020 ◽  
Vol 21 (18) ◽  
pp. 6664
Author(s):  
Panchanan Maiti ◽  
Jayeeta Manna ◽  
Zoe N. Burch ◽  
Denise B. Flaherty ◽  
Joseph D. Larkin ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Boronic Acid ◽  
Memory Function ◽  
Memory Deficits ◽  
Plaque Burden ◽  
Dot Blot ◽  
In Vivo Models

Alzheimer’s disease (AD) is characterized by amyloid (Aβ) aggregation, hyperphosphorylated tau, neuroinflammation, and severe memory deficits. Reports that certain boronic compounds can reduce amyloid accumulation and neuroinflammation prompted us to compare trans-2-phenyl-vinyl-boronic-acid-MIDA-ester (TPVA) and trans-beta-styryl-boronic-acid (TBSA) as treatments of deficits in in vitro and in vivo models of AD. We hypothesized that these compounds would reduce neuropathological deficits in cell-culture and animal models of AD. Using a dot-blot assay and cultured N2a cells, we observed that TBSA inhibited Aβ42 aggregation and increased cell survival more effectively than did TPVA. These TBSA-induced benefits were extended to C. elegans expressing Aβ42 and to the 5xFAD mouse model of AD. Oral administration of 0.5 mg/kg dose of TBSA or an equivalent amount of methylcellulose vehicle to groups of six- and 12-month-old 5xFAD or wild-type mice over a two-month period prevented recognition- and spatial-memory deficits in the novel-object recognition and Morris-water-maze memory tasks, respectively, and reduced the number of pyknotic and degenerated cells, Aβ plaques, and GFAP and Iba-1 immunoreactivity in the hippocampus and cortex of these mice. These findings indicate that TBSA exerts neuroprotective properties by decreasing amyloid plaque burden and neuroinflammation, thereby preventing neuronal death and preserving memory function in the 5xFAD mice.

Episodic memory function in advanced aging and early Alzheimer's disease

1995 ◽  
Vol 1 (1) ◽  
pp. 100-103 ◽  
Author(s):  
C. Munro Cullum ◽  
C. M. Filley ◽  
E. Kozora
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Episodic Memory ◽  
Memory Function ◽  
Good Health ◽  
Aging Effects ◽  
Memory Functions ◽  
Per Se ◽  
Early Alzheimer’S Disease ◽  
Distinguishing Features

AbstractDespite some well-documented differences, normal aging and Alzheimer's disease (AD) share a number of common neuropathological and neuropsychological features. Many of the reported differences are largely quantitative in nature and there is often overlap between the respective distributions of these populations. To assess the issue of overlap and distinguishing features in memory functions between these groups, and to minimize aging effects per se, samples of older individuals in good health (ages 75–95 yr) and younger patients in the early stages of AD (age < 75 yr) were selected to be similar in global cognitive functioning. Despite comparable language and visuospatial scores, these preliminary results suggest important qualitative differences in episodic memory functions between these conditions, even when “low-functioning” or “at-risk” controls are compared with early AD patients. These findings furthermore highlight some of the challenges in defining “normality” among the oldest segment of our population. (JINS, 1995, I, 100–103.)

[P4-158]: PRE-SCREENING FOR EPISODIC MEMORY DEFICITS CAN ENRICH FOR ELIGIBLE SUBJECTS IN EARLY ALZHEIMER's DISEASE CLINICAL TRIALS

2017 ◽  
Vol 13 (7S_Part_27) ◽  
pp. P1319-P1320
Author(s):  
Rosemary A. Abbott ◽  
Francesca K. Cormack ◽  
Sebastiaan Engelborghs ◽  
Maarten Timmers ◽  
Christopher Randolph ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Clinical Trials ◽  
Episodic Memory ◽  
Memory Deficits ◽  
Early Alzheimer’S Disease

scholarly journals Non-Alzheimer's disease-related memory impairment and dementia

2013 ◽  
Vol 15 (4) ◽  
pp. 465-473 ◽  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Memory Impairment ◽  
Clinical Symptoms ◽  
Memory Function ◽  
The Elderly ◽  
Memory Deficits ◽  
Common Cause ◽  
Underlying Causes ◽  
Therapeutic Possibilities

Although Alzheimer's disease (AD) is a common cause of memory impairment and dementia in the elderly disturbed memory function is a widespread subjective and/or objective symptom in a variety of medical conditions. The early detection and correct distinction of AD from non-AD memory impairment is critically important to detect possibly treatable and reversible underlying causes. In the context of clinical research, it is crucial to correctly distinguish between AD or non-AD memory impairment in order to build homogenous study populations for the assessment of new therapeutic possibilities. The distinction of AD from non-AD memory impairment may be difficult, especially in mildly affected patients, due to an overlap of clinical symptoms and biomarker alterations between AD and certain non-AD conditions. This review aims to describe recent aspects of the differential diagnosis of AD and non-AD related memory impairment and how these may be considered in the presence of memory deficits.

Sign in / Sign up

Export Citation Format

Share Document